Investment in Beijing, Winning the Future! Aimei Vaccine was invited to attend the first Zhongguancun Forum "Invest in Beijing Global Summit."
On May 26th, the "Invest in Beijing Global Summit," hosted by the Beijing Municipal Government, was held at the Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center. As a key investment attraction enterprise in the Beijing Economic and Technological Development Zone, Aimei Vaccine was invited to attend the summit and the signing ceremony for significant projects. As a leading domestic vaccine industry enterprise, Aimei Vaccine participated in the summit along with Fortune Global 500 companies, central enterprises, unicorn enterprises, fund companies, investment institutions, and other market entities.
It is reported that this summit, held during the Zhongguancun Forum for the first time, successfully signed 39 major projects, with a total contract value of 60.8 billion RMB. The Aimei Vaccine Headquarters Base and the Aimei Central Research Institute project were among them.
As a biological vaccine company based in the Beijing Economic and Technological Development Zone, Aimei Vaccine has always considered it a duty to produce ethical vaccines and benefit the health of people worldwide. Over the years, it has benefited from Beijing's reform and opening-up policies and favorable business environment and has developed into China's second-largest and the largest privately-owned full-industry-chain vaccine group, a leading enterprise in China's vaccine industry, one of the top three mRNA vaccine leaders in China, and was listed on the Hong Kong Stock Exchange in October 2022.
In the future, with new strengths and opportunities for development in Beijing, and strong support from the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Committee at all levels, Aimei Vaccine will continue to invest in the research and development of key products, expand its production capacity, and build comprehensive commercial capabilities. They will strive for further growth on the fast track of enterprise development, utilizing the advantages of technological innovation in biotechnology enterprises to contribute significantly to building Beijing as a major global center for scientific and technological innovation and a highland of innovation.
It is reported that this summit, held during the Zhongguancun Forum for the first time, successfully signed 39 major projects, with a total contract value of 60.8 billion RMB. The Aimei Vaccine Headquarters Base and the Aimei Central Research Institute project were among them.
As a biological vaccine company based in the Beijing Economic and Technological Development Zone, Aimei Vaccine has always considered it a duty to produce ethical vaccines and benefit the health of people worldwide. Over the years, it has benefited from Beijing's reform and opening-up policies and favorable business environment and has developed into China's second-largest and the largest privately-owned full-industry-chain vaccine group, a leading enterprise in China's vaccine industry, one of the top three mRNA vaccine leaders in China, and was listed on the Hong Kong Stock Exchange in October 2022.
In the future, with new strengths and opportunities for development in Beijing, and strong support from the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Committee at all levels, Aimei Vaccine will continue to invest in the research and development of key products, expand its production capacity, and build comprehensive commercial capabilities. They will strive for further growth on the fast track of enterprise development, utilizing the advantages of technological innovation in biotechnology enterprises to contribute significantly to building Beijing as a major global center for scientific and technological innovation and a highland of innovation.
